DEEJ(SZ:000423) Zheng Quan Ri Bao Wang·2025-12-04 13:26Core Viewpoint - Dong'e Ejiao plans to repurchase shares worth 100 million to 200 million yuan, marking its first share buyback since listing, aimed at enhancing shareholder value through share cancellation and improving financial metrics [1] Group 1: Share Buyback and Financial Strategy - The repurchased shares will be used for capital reduction, directly enhancing earnings per share and return on equity [1] - Since 2025, Dong'e Ejiao's total dividends and buyback amounts have exceeded 1.8 billion yuan, showcasing a strong commitment to shareholder returns [1] - The company has maintained a high cash dividend ratio, with cumulative dividends surpassing 10 billion yuan, positioning it favorably within the consumer sector and A-share market [1] Group 2: Financial Performance - In the first three quarters of this year, Dong'e Ejiao reported a net cash flow from operating activities greater than 1, supporting its ongoing dividend and buyback initiatives [2] - The company achieved a revenue of 1.716 billion yuan in Q3, reflecting an 8.5% year-on-year increase, and a net profit of 456 million yuan, up 10.27% [2] - The product portfolio includes core items like Ejiao blocks and compound Ejiao syrup, with a diversified product system driving growth [2] Group 3: Market and Industry Trends - The recovery of the pharmacy channel and the end of industry adjustments provide a favorable sales environment for Dong'e Ejiao [2] - The company has expanded its online sales through e-commerce and live streaming, increasing its revenue share from digital channels [3] - National policies promoting consumption are expected to benefit the food, beverage, and health sectors, positioning Dong'e Ejiao to capitalize on demand growth [3] - Stable medical insurance and centralized procurement policies create a supportive environment for traditional Chinese medicine companies, enhancing market opportunities for Dong'e Ejiao [3]